JP2022071077A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022071077A5 JP2022071077A5 JP2022031100A JP2022031100A JP2022071077A5 JP 2022071077 A5 JP2022071077 A5 JP 2022071077A5 JP 2022031100 A JP2022031100 A JP 2022031100A JP 2022031100 A JP2022031100 A JP 2022031100A JP 2022071077 A5 JP2022071077 A5 JP 2022071077A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- stereoisomer
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 3
- 229910052805 deuterium Inorganic materials 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 201000002471 spleen cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710493544 | 2017-06-26 | ||
| CN201710493544.X | 2017-06-26 | ||
| PCT/CN2018/092588 WO2019001383A1 (zh) | 2017-06-26 | 2018-06-25 | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 |
| JP2020520706A JP7374496B2 (ja) | 2017-06-26 | 2018-06-25 | Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520706A Division JP7374496B2 (ja) | 2017-06-26 | 2018-06-25 | Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022071077A JP2022071077A (ja) | 2022-05-13 |
| JP2022071077A5 true JP2022071077A5 (enExample) | 2022-08-08 |
Family
ID=63772870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520706A Active JP7374496B2 (ja) | 2017-06-26 | 2018-06-25 | Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 |
| JP2022031100A Withdrawn JP2022071077A (ja) | 2017-06-26 | 2022-03-01 | Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520706A Active JP7374496B2 (ja) | 2017-06-26 | 2018-06-25 | Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11718611B2 (enExample) |
| EP (1) | EP3626241B1 (enExample) |
| JP (2) | JP7374496B2 (enExample) |
| CN (2) | CN110759908B (enExample) |
| ES (1) | ES3028360T3 (enExample) |
| WO (1) | WO2019001383A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111747949B (zh) * | 2019-03-29 | 2022-07-01 | 首药控股(北京)股份有限公司 | Bcl-2选择性抑制剂的制备方法 |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| CN116969937B (zh) | 2020-04-15 | 2026-03-24 | 百济神州(苏州)生物科技有限公司 | Bcl-2抑制剂 |
| CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
| CN115697967B (zh) * | 2020-07-10 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用 |
| CN114835704B (zh) * | 2021-02-01 | 2023-10-27 | 苏州亚盛药业有限公司 | 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物 |
| US20240408085A1 (en) * | 2021-09-01 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Compound for degradation of bcl-2 family proteins and medical application thereof |
| WO2024032776A1 (en) * | 2022-08-12 | 2024-02-15 | Fochon Biosciences, Ltd. | Compounds as bcl-2 inhibitors |
| CN115286689B (zh) * | 2022-09-29 | 2023-01-06 | 上海睿跃生物科技有限公司 | 靶向降解Bcl-2蛋白的化合物及其应用和药物 |
| CN115872963A (zh) * | 2022-12-27 | 2023-03-31 | 南京哈柏医药科技有限公司 | 一种维奈托克中间体的合成方法 |
| CN118373787A (zh) * | 2024-04-26 | 2024-07-23 | 苏州九鹭生物医药有限公司 | 一种氘代n-酰基磺酰胺类化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US20100160322A1 (en) * | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2546294T7 (es) | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| RU2593231C2 (ru) * | 2010-11-23 | 2016-08-10 | ЭббВи Айэленд Анлимитед Компани | Способы лечения с использованием селективных ингибиторов bcl-2 |
| CN103987711B (zh) * | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP3481397A1 (en) * | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
-
2018
- 2018-06-25 JP JP2020520706A patent/JP7374496B2/ja active Active
- 2018-06-25 ES ES18824477T patent/ES3028360T3/es active Active
- 2018-06-25 WO PCT/CN2018/092588 patent/WO2019001383A1/zh not_active Ceased
- 2018-06-25 EP EP18824477.6A patent/EP3626241B1/en active Active
- 2018-06-25 US US16/625,025 patent/US11718611B2/en active Active
- 2018-06-25 CN CN201911104054.1A patent/CN110759908B/zh active Active
- 2018-06-25 CN CN201810661179.3A patent/CN108658983B/zh active Active
-
2022
- 2022-03-01 JP JP2022031100A patent/JP2022071077A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012153722A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| CN115803325A (zh) | 一种egfr抑制剂及其制备方法和应用 | |
| JP2024522766A5 (enExample) | ||
| JP2014500870A5 (enExample) | ||
| JP2021520372A5 (enExample) | ||
| JP2022544656A5 (enExample) | ||
| JP2013518089A5 (enExample) | ||
| JP2020007311A5 (enExample) | ||
| JP2021512166A5 (enExample) | ||
| JP2006501176A5 (enExample) | ||
| JP2020511467A5 (enExample) | ||
| RU2020102453A (ru) | Фармацевтические композиции | |
| JP2013522292A5 (enExample) | ||
| JP2009525353A5 (enExample) | ||
| JP2014502599A5 (enExample) | ||
| JP2008528671A5 (enExample) | ||
| JP2017530171A5 (enExample) | ||
| JP2020507566A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| JP2015504075A5 (enExample) | ||
| JP2022500383A5 (enExample) | ||
| RU2014101626A (ru) | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты | |
| JP2012509265A5 (enExample) |